Managing CLL after BTK and BCL-2 inhibitors
Jonathan Moore
Treatment-free remission in CML: who, when and how
Ana Nikolić
Anemia in myelofibrosis
Brian Edwards
Patient blood management in 2024
Antonio Marchetti
Chronic lymphocytic leukemia: first-line treatment
Anna Lehmann
Chronic myeloid leukemia: first-line treatment
Óscar Hernández
Myeloproliferative neoplasms: first-line treatment
Mathieu Muller
Transfusion medicine: emerging therapies
Péter Farkas
Chronic lymphocytic leukemia: managing relapse
Alexander Müller
Chronic myeloid leukemia: managing relapse
Lena Schwarz
Myeloproliferative neoplasms: first-line treatment
Ana Costa
Transfusion medicine: diagnosis and risk assessment
Miriam Schröder
Zelvudocel versus inotuzumab ozogamicin in T-cell ALL (NORDLYS-8): a phase 1b/2 trial
Nicole Kaiser
Efficacy and safety of menavostat in AML in first complete remission: primary analysis of the phase 1b/2 ECLIPSE-8 study
Joana Almeida
Real-world effectiveness of concivumab in people with severe hemophilia A: a multicenter european cohort
Rachel Evans
Complex karyotype predicts outcome in CLL with del(17p) or TP53 mutation
Vasiliki Alexiou
Orvematinib plus dasatinib in CML after two or more tyrosine kinase inhibitors: randomized phase 2 results of the CORONA-8 trial
Elisa Ricci
Fetal hemoglobin induction predicts outcome in transfusion-dependent beta-thalassemia
Karim Ibrahim
Prognostic value of IKZF1 deletions in T-cell ALL: results from TRIDENT-4
Maximilian Richter
Single-cell profiling reveals leukemic stem cell persistence in acute myeloid leukemia (AML)
Nour Saad
Real-world effectiveness of concivumab in cancer-associated venous thromboembolism: a multicenter german cohort
Uri Weiss
Health-related quality of life in fit patients with untreated CLL: a prospective french study
Felix Klein
Early molecular response at 3 months predicts outcome in CML after two or more tyrosine kinase inhibitors
Silvia Valentini
Prognostic value of HSC quiescence markers in aged mice: results from CORONA-3
Jonas Möller
Targeting leukemia-niche interactions in acute lymphoblastic leukemia (ALL): preclinical evidence
Hugo David
Single-cell profiling reveals immune evasion in the bone marrow niche in acute myeloid leukemia (AML)
Andrea Schmitt
Real-world effectiveness of abelorimab in people with severe hemophilia A: a multicenter spanish cohort
Stefan Hoffmann
Real-world effectiveness of pirvabrutinib in older patients with CLL and comorbidities: a multicenter dutch cohort
Judith Peters
Prognostic value of early molecular response at 3 months in chronic-phase CML in deep molecular response: results from CORONA-8
Panagiotis Pappas
Multi-omic characterization of inflammatory aging of the stem cell niche in human cord blood
James Turner
Efficacy and safety of ibrexitamab in adolescents and young adults with ALL: primary analysis of the randomized phase 3 ARCTIC-7 study
Samir Nasser
Clonal hematopoiesis predicts outcome in adults with newly diagnosed AML receiving intensive induction
Rubén Serrano
Single-cell profiling reveals tissue factor pathway regulation in bleeding and thrombotic disorders
Iván Blanco
Efficacy and safety of tovaclax in older patients with CLL and comorbidities: primary analysis of the randomized phase 3 PRISM-3 study
Mathieu Garnier
Ascavinib versus nilotinib in newly diagnosed chronic-phase CML (SUMMIT-4): a phase 3 trial
Christina Köhler
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Maximilian Schmitt
Real-world effectiveness of zelvudocel in T-cell ALL: a multicenter british cohort
Julien Legrand
Efficacy and safety of tozarinib in newly diagnosed AML patients ineligible for intensive chemotherapy: primary analysis of the phase 1 ARCTIC-5 study
Frida Lindberg
Rilvabrutinib plus low-molecular-weight heparin in people with severe hemophilia A: randomized phase 3 results of the VALOR-4 trial
David Blanco
Long-term outcomes of newly diagnosed chronic-phase CML treated with nilotinib: a Nordic registry study of 231 patients
Pilar Ramos
Treatment patterns and survival in patients with sickle cell disease treated with gene editing: real-world data from the Spanish cell therapy registry
Javier Gómez
Multi-omic characterization of epigenetic memory after infection in aged mice
Ulrike Beck
Menavostat versus cytarabine and daunorubicin in adults with newly diagnosed AML receiving intensive induction (POLARIS-7): a phase 1 trial
Serena Colombo
Marsatimab versus thrombopoietin receptor agonists in adults with immune thrombocytopenia (AURORA-6): a phase 2 trial
Aurélie Henry
Real-world effectiveness of nelbrutinib in older patients with CLL and comorbidities: a multicenter nordic cohort
Johanna Fuchs
Prognostic value of early molecular response at 3 months in CML after two or more tyrosine kinase inhibitors: results from ARCTIC-8
Raquel Alonso
Zelvudocel plus busulfan myeloablation in patients with sickle cell disease treated with gene editing: phase 1 results of the ATLAS-1 trial
Miriam Neumann
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Alessandro Ricci
Nordheim Pharma Satellite Symposium: Redefining depth of response in multiple myeloma
Fabio Martini, Jan Novák, Fatma Özdemir
Corvalis Biotherapeutics Satellite Symposium: Bispecific antibodies across lines of therapy in B-cell lymphoma
Chen Huang, Anastasia Oikonomou, Antonio Marchetti
Hemavera Therapeutics Satellite Symposium: Iron, inflammation and anemia: new targets
Akiko Kimura, Bo Liu, Ioannis Angelopoulos
Immune thrombocytopenia in adults
Chen Huang
Follicular lymphoma in 2024
Lorenzo Conte
Inflammation and the aging stem cell
Anastasia Oikonomou
Artificial intelligence in the hematology laboratory
Dimitrios Makris
Bleeding, thrombosis and platelets: long-term follow-up
Bas van der Meer
Lymphoma: first-line treatment
Jessica Turner
Hematopoiesis and stem cell biology: diagnosis and risk assessment
Tiago Oliveira
Novel technologies and AI: diagnosis and risk assessment
Lars Halvorsen
Bleeding, thrombosis and platelets: long-term follow-up
Daniel Brown
Lymphoma: managing relapse
Omar Najjar
Hematopoiesis and stem cell biology: diagnosis and risk assessment
Rafael Santos
Novel technologies and AI: managing relapse
Adrián Marín
Opening plenary lecture: Hematology at the frontier of cell and gene therapy
Bo Zhu
Plenary lecture: Clonal hematopoiesis, aging and disease
Joon-young Jang